NASH Core Curriculum: NASH Pathogenesis

Expert commentary discussing the complex interplay among NASH, obesity, and diabetes from Clinical Care Options (CCO)

Brent A. Neuschwander-Tetri, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 29, 2021 Expired: January 28, 2022

Kenneth Cusi, MD, FACP, FACE, and Stephen A. Harrison, MD, COL (Ret.), FAASLD, explain how to interpret endpoints used in NASH studies so you can evaluate emerging treatments

Kenneth Cusi, MD, FACP, FACE
Program Director Stephen A. Harrison, MD, COL (Ret.), FAASLD Released: March 26, 2019

Raymond E. Soccio, MD, PhD, summarizes the roles of weight loss and diabetes drugs in NASH

Raymond E. Soccio, MD, PhD Released: March 7, 2019

Philip N. Newsome, PhD, FRCPE, summarizes the roles of weight loss and diabetes drugs in NASH

Philip N. Newsome, PhD, FRCPE Released: March 6, 2019